Gufic Biosciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gufic Biosciences submitted its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26). Standalone revenue from operations grew about 12% year-on-year to Rs. 22,691 lakhs (from Rs. 20,281 lakhs). However, net profit dropped sharply by around 42% to Rs. 1,207 lakhs (from Rs. 2,086 lakhs), as total expenses rose nearly 20% driven by higher raw material costs and other expenses. Consolidated revenue rose to Rs. 22,372 lakhs while consolidated net profit fell to Rs. 1,307 lakhs. The statutory auditors issued a clean limited review report with no qualifications. The board also re-appointed M/s. Poddar & Co. as cost auditors for FY25-26 and M/s. Mittal Agarwal & Co. as statutory auditors for a second 5-year term up to 2030.
Despite healthy topline growth, the steep fall in profit reflects significant cost pressure and margin compression, which is likely to weigh on investor sentiment and the stock in the short term. Re-appointment of existing auditors signals continuity but does not change the near-term earnings narrative.